Table 5 Prognostic significance of natriuretic peptides in COPD
From: B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review
| Â | n | Follow up | Echo (%) | Heart failure details | Natriuretic peptide threshold | Endpoints | Unadjusted risk | Adjusted risk |
|---|---|---|---|---|---|---|---|---|
Stable | ||||||||
Inoue [35] | 60 | 3 years | 53 | 6% <50% | BNP > 34.2 | death exacerbation | not significant increased | not significant HR 3.8 (1.2–12.7) p = 0.02 |
Gale [25] | 140 | 1 year | 100 | 11% EF < 45% | highest vs lowest quartile | death hospitalization | RR 3.0 (p = 0.001) | not significant not significant |
Waschki [48] | 170 | 48 months | 100 | – | – | death | HR 1.47 (1.05–2.06) | 1.16 (0.97–1.39) |
Andersen [42] | 117 | 2.8 years | 100 | – | NT-proBNP <95 ng/L | death | HR 0.29 (0.09–0.97) p = 0.04 | – |
van Gestel [49] | 144 | 1 year | 100 | ex EF ≤ 40% | NT-proBNP >500 pg/ml | death | HR 4.5 (1.5–13.5) | HR 7.7 (1.6–37.4) |
Zeng [50] | 220 | 22 months | – | 26% HF | – | death | – | 1.61 (1.27–2.06) |
Exacerbation | ||||||||
Stolz [33] | 208 | 2 year | 75 | 10% LVSD | per 100 pg/ml | death ICU admission | not significant 1.12 (1.03–1.22) | not significant 1.13 (1.0–1.24) |
Lee [51] | 67 | inpatient | – | – | BNP >88 pg/ml | death | – | OR 21.2 (2.5–180.4) |
Chang [44] | 244 | 1 year | 0 | acute cardiac disease ex | NT-proBNP >220 pmol/L | death 30 day death 1 year | OR 9.0 (3.1 – 26.2) p < 0.001 1 year not significant | OR 7.5 (1.9–28.9) p = 0.004 1 year not significant |
Marcun [34] | 127 | 6 month | 100 | 13% EF < 55% 42% DD | age/gender adjusted | death hospitalization | HR 5.49 (1.25-24.00) HR 1.34 (0.84-2.63) | HR 4.20 (1.07-14.01) HR 1.48 (0.60-3.69) |
Medina [52] | 192 | 1 year | 0 | exclude prior | NT-proBNP >588 pg/ml | death | OR 3.90 (1.46-10.47) p = 0.006 | OR 3.30 (1.11–9.85) p = 0.034 |
Hoiseth [45] | 99 | median 1.9 years | 0 | 21% vs 9% tertile 3 vs 1 | tertile 3 vs 1 | death | HR 6.9 (3.0 – 16.0) p < 0.0001 | HR 3.2 (1.3–8.1) p = 0.012 |